LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

[ad_1] Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory…